Hematology/Oncology News

Lack of health insurance contributes to a high percentage of racial and ethnic disparities in advanced-stage diagnoses for several cancer types, according to results of a mediation analysis.

Researchers reported beneficial effects of a supervised exercise intervention on breast cancer outcomes, according to preliminary findings from the OptiTrain trial presented at ESMO Congress.

Breast cancer survivors who participated in a remote personalized exercise program experienced modest improvements in quality of life, according to results from the eMouvoir trial presented at ESMO Congress.

A telephone-based weight loss intervention significantly increased moderate or vigorous physical activity in patients with breast cancer with overweight/obesity, according to a breast cancer weight loss trial presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

Daylight saving time has been a source of contention and debate since its introduction in 1918.

The FDA granted accelerated approval to asciminib for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

The FDA has expanded the approval of an oral liquid methotrexate solution to include children and adolescents with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia, according to a press release.